William Blair Issues Optimistic Forecast for IPSC Earnings

Century Therapeutics, Inc. (NASDAQ:IPSC) – Equities researchers at William Blair increased their Q1 2025 earnings per share (EPS) estimates for shares of Century Therapeutics in a note issued to investors on Thursday, March 20th. William Blair analyst S. Corwin now anticipates that the company will earn ($0.45) per share for the quarter, up from their previous estimate of ($0.46). The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.61) per share. William Blair also issued estimates for Century Therapeutics’ Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.79) EPS, Q1 2026 earnings at ($0.46) EPS, Q2 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.48) EPS and FY2026 earnings at ($1.89) EPS.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.02. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. The business had revenue of $4.18 million for the quarter, compared to analyst estimates of $0.67 million.

A number of other research firms have also commented on IPSC. Chardan Capital reduced their price target on shares of Century Therapeutics from $11.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday. Guggenheim reduced their target price on Century Therapeutics from $12.00 to $5.00 and set a “buy” rating on the stock in a report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Century Therapeutics in a report on Wednesday, January 22nd. Finally, Piper Sandler cut their price objective on Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating for the company in a research report on Thursday, March 20th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Century Therapeutics currently has a consensus rating of “Buy” and an average target price of $5.00.

Century Therapeutics Stock Performance

IPSC opened at $0.58 on Monday. The firm has a market cap of $49.63 million, a price-to-earnings ratio of -0.32 and a beta of 1.75. The firm’s 50-day simple moving average is $0.74 and its 200-day simple moving average is $1.15. Century Therapeutics has a twelve month low of $0.52 and a twelve month high of $4.50.

Institutional Trading of Century Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Marshall Wace LLP bought a new position in Century Therapeutics in the 4th quarter valued at $36,000. Jane Street Group LLC lifted its stake in shares of Century Therapeutics by 166.2% during the fourth quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock valued at $49,000 after acquiring an additional 29,992 shares during the period. Two Sigma Advisers LP bought a new position in Century Therapeutics in the fourth quarter valued at about $52,000. Sei Investments Co. bought a new position in Century Therapeutics in the fourth quarter valued at about $53,000. Finally, Two Sigma Investments LP acquired a new stake in Century Therapeutics in the fourth quarter worth about $67,000. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.